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 INTRODUCTION 
 
Breast cancer, which is the most common malignancy in 
women, was found to have association with  estrogen  The discovery 
of the estrogen receptor produced vast changes in the management 
of cancer breast .It is an important prognostic marker. 
 
On treating patients with carcinoma of the breast we are often 
confronted with the dilemma of how to identify those patients who 
are most likely to benefit from hormonal treatment. Estrogen 
receptor rich tumors respond to hormone therapy more frequently 
than do estrogen receptor poor tumors. Estrogen receptor status is 
the most important indicator in predicting the response of advanced 
breast cancer to hormonal manipulation and possibly chemotherapy. 
    
  
 
AIM AND OBJECTIVES 
 
The aim of this work is: 
1. To study the pattern of Estrogen Receptor status in female 
patients with breast cancer. 
2. To find out eventual correlation between Estrogen Receptor 
status and menstrual status. 
3. To predict the value of Estrogen Receptor status in choosing 
patients for adjuvant hormonal treatment. 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 The levels of estrogen receptors had been studied in many 
cases of primary carcinoma of the breast and it was found that 
percentage of patients with estrogen receptor positive carcinomas 
was higher in postmenopausal group. 
 
 Relationship of age and menopausal status to estrogen receptor 
content in primary carcinoma of the breast was studied from the 
departments of medicine, pathology, surgery and biochemistry, 
Duke University Medical Center, Durban, North Carolina and was 
published in Annals  of Surgery, February 1983, Vol 197. 
 
 The cytosolic estrogen receptor (CER) content of 1037 
primary breast carcinomas was evaluated by sucrose density gradient 
analysis. Tumor specimens from premenopausal patients had 
significantly lower level of cytosolic estrogen receptor compared 
with carcinomas from postmenopausal patients. 
The initial report by Jensen et al. said that the measurement of 
Cytosolic Estrogen Receptor content in metastatic breast carcinoma 
tissue was useful in predicting response to endocrine therapy. This 
determination has been widely used to select therapy. It has also 
been reported that patients with primary tumors that were CER rich 
experienced improved survival compared with patients whose 
carcinomas are CER poor. Compared with premenopausal patients, 
postmenopausal patients have quantitatively higher levels of CER 
and a greater proportion of their tumors are CER positive. 
 
 
 
 
 
 
 
 
 
 
 
 
                 SURGICAL ANATOMY OF BREAST 
 
 
 
 
 
 ROLE OF ESTROGEN IN DEVELOPMENT OF BREAST 
 
 The major hormonal influence on the breast is estrogen. The 
initial immaturity of the hypothalamic–pituitary axis results in 
anovulatory cycles for the first 1–2 years after menses begin, 
subjecting the breast to the effects of unopposed estrogen. It is 
during this period of unopposed estrogen stimulation, considered an 
“Estrogen Window” that the ductal growth phase occurs. 
 
 A potent mammogen, estrogen primarily stimulates ductal 
growth but also increases fat deposition and contributes to later 
phases of development. Impaired ductal growth has been 
demonstrated in both people lacking the functional gene for the 
estrogen receptor (ER) and people treated with tamoxifen, an ER 
modulator. The estrogen receptor ER α is thought to be the key 
mediator of estrogen effects and in humans has only been 
documented in luminal epithelium. 
 
 
EPIDEMIOLOGY OF BREAST CANCER 
  
 The incidence rates of breast cancer increased in most 
countries through the 1990s. Since the estimates for 1990, there was 
an overall increase in incidence rates of approximately 0.5% 
annually. 
 Recent data from the SEER program reveal declines in breast 
cancer incidence over the past decade and this is widely attributed to 
decreased use of hormone replacement therapy. 
 Breast cancer burden has well-defined variations by 
geography, regional lifestyle and racial or ethnic background. In 
general, both breast cancer incidence and mortality are relatively 
lower among the female populations of Asia and Africa, relatively 
underdeveloped nations and nations that have not adopted the 
westernized reproductive and dietary patterns. In contrast, European 
and North American women and women from heavily industrialized 
or westernized countries have a substantially higher breast cancer 
burden. These international patterns are mirrored in breast cancer 
incidence and mortality rates. 
 Although often related the factors that influence breast cancer 
incidence may differ form those that affect mortality. Incidence rates 
are lower among populations that are heavily weighted with women 
who begin childbearing at young ages and who have multiple full-
term pregnancies followed by prolonged lactation. 
 
 Breast cancer mortality rates should be lower in populations 
that have a lower incidence, but the mortality burden will 
simultaneously be adversely affected by the absence of effective 
screening programs for early detection and diminished access to 
multidisciplinary cancer treatment programs. These features are 
likely to account for much of the disproportionate mortality risks 
that are seen in underdeveloped nations. 
  
TRADITIONAL RISK FACTORS FOR BREAST CANCER 
 
RISK FACTOR COMPARISON 
CATEGORY 
RISK CATEGORY 
Age at menarche 16 years Younger than 12 years 
Age at menopause 45 – 54 years After 55 years 
Age when first child 
born alive 
Before 20 years Nulliparous or older than 
30 years 
Benign breast 
disease 
No biopsy or fine 
needle aspiration 
Any benign disease 
Proliferative disease 
Atypical hyperplasia 
Family history of 
breast cancer 
No first degree 
relative affected 
Mother affected 
Two first degree relatives 
affected 
 
  
NEWER EPIDEMIOLOGIC RISK FACTORS FOR BREAST 
CANCER 
 
CHARACTERISTIC MENOPAUSAL 
STATUS 
COMPARISON 
CATEGORY 
RISK 
CATEGORY 
Circulating estradiol premenopausal Lowest quartile Highest 
quartile 
Postmenopausal Lowest quartile Highest 
quartile 
Circulating estrone premenopausal Lowest quartile Highest 
quartile 
Postmenopausal Lowest quartile Highest 
quartile 
 
  
NEWER EPIDEMIOLOGIC RISK FACTORS FOR BREAST 
CANCER 
CHARACTERISTIC MENOPAUSAL 
STATUS 
COMPARISON 
CATEGORY 
RISK 
CATEGORY 
Genetic factors 
BRCA 1 mutation 
 
Both 
 
No mutation 
 
Mutation present 
in gene 
BRCA 2 mutation  
Both 
 
No mutation 
 
Mutation present 
in gene 
Hormonal factors 
Oral contraceptive 
use 
 
Both 
 
Never users 
 
Current users 
Both Never users >10 years 
since last use 
Hormone therapy 
use 
Post 
menopausal 
Non users with 
an intact uterus 
Estrogen + 
progestin users 
Non users with a 
hysterectomy 
Estrogen users 
 
 
 
 
  
 
 
REPRODUCTIVE FACTORS 
 
CHARACTERISTIC MENOPAUSAL 
STATUS 
COMPARISON 
GROUP 
REFERENCE GROUP 
Parity Both 2 live birth Nulliparous 
Breast feeding Premenopausal Ever breastfed Never breastfed 
 Postmenopausal Ever breastfed Never breastfed 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
BEHAVIOURAL FACTORS 
 
CHARACTERISTIC MENOPAUSAL 
STATUS 
COMPARISON 
CATEGORY 
REFERENCE 
CATEGORY 
BMI Postmenopausal <21 Kg per m2 >33 Kg per m2 
Premenopausal <21 Kg per m2 >33 Kg per m2 
Height Postmenopausal <1.60 m >1.75 m 
Premenopausal <1.60 m >1.75 m 
Weight Postmenopausal <60 Kg >80 Kg 
Premenopausal <60 Kg >80 Kg 
Alcohol use Both Never drunkers >12 g per day 
Smoking Both Never smokers Smoked >40 
years 
 
 
 
 
 
 SIGNS AND SYMPTOMS OF BREAST CANCER 
1. Mass or swelling in the breast 
2. Nipple ulceration 
3. Nipple  retraction 
4. Peaud orange 
      5.Ulceration or fungation of breast 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
DIAGNOSTIC STUDIES FOR BREAST CANCER PATIENTS 
CANCER STAGE 
 
 0 I II III IV 
History & physical examination X X X X X 
Complete blood count  X X X X 
Liver function test  X X X X 
Chest radiograph  X X X X 
Hormone receptor status  X X X X 
HER- 2/neu expression  X X X X 
Bone scan   X X X 
CECT abdomen or ultrasound   X X X 
;. 
 
 
 
 
 
 
 MANAGEMENT OF CA BREAST 
Surgical treatment  
- Total Mastectomy 
- Breast Conservation Therapy 
 
Management of axilla 
- SLN dissection 
- Axillary node dissection 
 
Chemotherapy 
- Adjuvant 
- Neoadjuvant 
 
Endocrine therapy 
Radiation therapy 
Immuno therapy 
 
 
 
 
 HISTORY OF HORMONAL THERAPY AND                    
ESTROGEN RECEPTORS 
 
Hormonal treatment for breast cancer was considered even 
before the beginning of the twentieth century. In 1889, Albert 
Schinzinger of Freiburg , Germany , proposed oophorectomy before 
mastectomy to knock off estrogen in menstruating women .  
 
          In 1973, W.Mc Guire demonstrated estrogen receptors in 
human breast tumors. In 1975, K. Horowitz identified progesterone 
receptors in hormone – dependent breast cancer .Since the 1980s, 
tamoxifen and other selective estrogen receptor modulators 
(SERMs) have been used for the treatment and prevention of breast 
cancer.  
 
 
HISTORICAL BACKGROUND OF HORMONAL THERAPY 
           In the mid 1980s  Dr.George T.Beatson presented a paper to 
the Edinburgh Medico–Chirurgical society stating that 
oophorectomy in rabbits resulted in loss of lactation . This led to the 
hypothesis that lactation is controlled by the ovaries and that 
removal of the ovaries could potentially benefit patients with breast 
cancer. 
           Based on his hypothesis, Dr.Beatson performed an 
oophorectomy on June 15, 1895 on a premenopausal patient with 
advanced, unresectable breast cancer with soft tissue recurrence . 
The patient showed clinical improvement, had a complete remission 
and survived four years after the surgery. This finding was the first 
clinical evidence that breast cancer may be dependent on ovarian 
function . 
                 The benefit of oophorectomy in some breast cancer 
patients was confirmed by Dr.Stanley N.Boyd with a case report and 
a subsequent series of 46 premenopausal women with advanced 
breast cancer.          
  
 
 
 
 
 
 
                   
   ADJUVANT ENDOCRINE THERAPY 
         Tamoxifen is the historic standard for adjuvant endocrine 
therapy for breast cancer. Tamoxifen administered for five years 
results in a 41% reduction in the annual rate of breast cancer 
recurrence  and 34% reduction in annual death rate for women with 
estrogen receptor positive breast cancer . 
 
        Shorter  durations of tamoxifen therapy  are also beneficial , but 
appear to have less impact than 5 year treatment duration. The 
optional duration of tamoxifen therapy appears to be 5 years ; 
extending tamoxifen therapy beyond 5 years in patients with no 
evidence of tumor recurrence has not led to further improvement in 
disease free or overall survival. Consistent with its activity as a 
SERM, tamoxifen is not effective in preventing recurrence of 
hormone receptor negative breast cancer. 
 
 
ENDOCRINE THERAPY IN DCIS 
          Two prospective randomised trials have evaluated the effect of 
tamoxifen on outcome in patients with DCIS treated with breast 
conserving therapy. In the NSABP B – 24 trial, 1804 women with 
DCIS were randomly assigned to breast conserving surgery and 
radiation therapy followed by either tamoxifen at 20 mg / day or a 
placebo for 5 years. At 7 years of follow up, women who received 
tamoxifen had fewer breast cancer events than did placebo group 
(10%  vs. 16.9%) . Among those who received tamoxifen, the rate of 
ipsilateral invasive breast cancer was 2.6% at 7 years compared  to 
5.3% in the control group. Tamoxifen also decreased the 7-year 
cumulative incidence of contralateral breast neoplasms (invasive and 
non invasive ) to 2.3% compared with 4.9% in the control group. 
           A subgroup analysis, based on estrogen receptor status, 
indicated that women with estrogen receptor positive DCIS  who 
received tamoxifen had a 59% reduction in their  relative risk of 
breast cancer events  when compared with those who received the 
placebo .Among patients with estrogen receptor negative DCIS there 
was no added benefit from tamoxifen. 
          The decision of whether to use adjuvant tamoxifen for patients 
with DCIS should be made on an individual basis. The use of 
tamoxifen has been associated with vasomotor symptoms, deep vein 
thrombosis, pulmonary embolism and increased cataract formation. 
The risk of endometrial cancer is increased two to seven times 
among patients who receive the drug. Tamoxifen is also associated 
with increased risk of stroke and benign ovarian cysts. Therefore, the 
effects of tamoxifen to reduce ipsilateral breast tumors and to 
prevent contralateral breast disease should be weighed against the 
risk of tamoxifen use in each patient. In addition, tamoxifen should 
be reserved for patients with estrogen receptor positive tumors. 
           Aromatase inhibitors have been shown to be beneficial in the 
adjuvant treatment of breast cancer in postmenopausal women with 
estrogen receptor positive disease. These agents have fewer 
cardiovascular side effects than tamoxifen and may be beneficial in 
the adjuvant treatment of patients with DCIS following breast 
conserving surgery. 
 
 
ENDOCRINE THERAPY IN LCIS 
                    For patients with a diagnosis of LCIS, one of the 
treatment options is chemoprevention with tamoxifen . In the 
NSABP P-1 breast cancer prevention trial , Fisher et al. (1998)  
observed a 56%  decrease in the incidence of invasive breast cancers 
in the subset of women with LCIS who received tamoxifen as 
compared with women  with LCIS who underwent observation 
alone. The annual hazard rate of invasive cancer was 5.69 per 1000 
women who received tamoxifen compared with 12.99 per 1000 
women who did not. 
 
             In the NSABP P-2 trial, postmenopausal women with LCIS 
were eligible to be randomised between tamoxifen and raloxifene. 
Vogel et al.(2006) reported  that the two agents offered an equivalent 
risk reduction for invasive breast cancer (incidence 4.30 per 1000 vs. 
4.41 per 1000, for tamoxifen and raoxifen, respectively). Patients 
receiving raloxifen had a lower risk of thromboembolic events and 
cataracts. 
Vogel et al. concluded that depending on an individual’s  
personal risk factors, both raloxifen and tamoxifen are valuable for 
breast cancer risk reduction. Raloxifen may be particularly beneficial 
to a postmenopausal women with an intact uterus who also faces a 
risk of osteoporosis. 
 
 
 
 
 
 
 
 
 
 
 
ENDOCRINE THERAPY IN INVASIVE BREAST CANCER 
Endocrine therapy has been associated with significant reductions in   
 1.  Risk of  local recurrence 
2. Distant metastasis 
  3. Contralateral breast cancer 
 
 
 
 
 
 
 
 
 
 
Tamoxifen therapy 
          Tamoxifen which was originally recommended for the 
treatment of postmenopausal women with ER – positive breast 
cancer ,  is now indicated for a much broader range of patients. 
Tamoxifen therapy is considered standard of care for premenopausal 
women with tumors expressing estrogen receptor , regardless of age 
or nodal status. 
          Tamoxifen therapy is generally well tolerated ; treatment 
limiting adverse effects develop in less than 5% of  patients. In 
addition to its antitumor properties, tamoxifen increases bone density 
and reduces serum cholesterol levels. However, tamoxifen also 
increases the incidence of endometrial cancer and thrombo embolic 
events. 
          A meta – analysis  of five randomized clinical trials showed 
that patients who were treated with tamoxifen for 3-5 years  had a 
greater reduction in recurrence than did patients treated for 1 to 2 
years . Data from NSABP B-14 indicated that 10 years of tamoxifen  
offer  no survival advantage over 5 years. 
          Most recently in the  EBCTCG  analysis, in women with ER-
positive tumors were randomised to receive 5 years of adjuvant 
tamoxifen, there was a 41 %  proportional risk reduction of 
recurrence and there was a 34%  proportional risk reduction of 
mortality compared with those who did not receive tamoxifen. 
Currently 5 years of adjuvant tamoxifen is considered the standard 
therapy for premenopausal women. 
          Current ASCO recommendations for postmenopausal women 
include an aromatase inhibitor as a component of adjuvant endocrine 
therapy. The aromatase inhibitors anastrazole, letrozole and 
exemestane work by inhibiting the aromatase enzyme that catalyses  
the conversion of adrenal corticosteroids to estrogens and therefore 
decreases the conversion of precursor hormones to estrogen in 
adipose tissue . 
           In the ATAC (Arimidex, Tamoxifen Alone or in 
combination) trial, the efficacy and side effect profiles of anastrazole 
and tamoxifen were compared in postmenopausal women. For 
postmenopausal patients with early stage breast cancer, anastrazole 
resulted in a higher DFS rate ( 86.9% vs. 84.5% )  than tamoxifen , 
longer time to recurrence and  lower incidence of contralateral breast 
cancer.  
             The results also demonstrated that the incidence of 
endometrial cancer, vaginal bleeding and discharge, cerebrovascular 
events, venous thromboembolic events and hot flushes occurred 
significantly less frequently witn anastrazole; whereas 
musculoskeletal disorders and fractures occurred less frequently with 
tamoxifen. As a result of ATAC trial, anastrazole is now the 
preferred hormone therapy for postmenopausal patients with 
receptor positive breast cancer. 
 
 
 
 
 
 
 
ENDOCRINE THERAPY IN ER POSITIVE CASES 
            The estrogen receptor is present in about in 80% of DCIS 
lesions and is more frequent in non comedo than comedo DCIS. 
Endocrine therapy has two potential benefits in women with breast 
cancer : a reduction in local recurrence after breast conserving 
therapy and the prevention of the development of new primary 
breast cancers in the contralateral breast . 
              In women with ER – positive breast cancer, tamoxifen 
reduced the risk of any breast cancer event by 59 % . In women with 
ER – negative tumors, no significant benefit was seen. 
 
 
 
 
 
 
 
  
 
Overview of Adjuvant Treatment Approaches in Breast Cancer 
 Hormone Receptor 
Status POSITIVE 
Hormone Receptor 
Status NEGATIVE 
Tumor HER Status POSITIVE NEGATIVE 
HER-2 negative / 
normal 
Endocrine therapy 
+Chemotherapy 
Chemotherapy 
HER-2 positive / 
overexpressed 
Endocrine therapy + 
Chemotherapy + 
Trastuzumab 
Chemotherapy + 
Trastuzumab 
 
 
 
 
 
 
 
 ENDOCRINE THERAPIES USED FOR  METASTATIC 
BREAST  CANCER 
 
Aromatase Inhibitors 
Non-steroidal         
Anastrazole 1 mg orally 
daily 
Hot flushes , arthralgias , myalgias, 
headaches , diarrhoea , mild nausea 
Letrozole 2.5 mg 
orally daily 
 
 
Steroidal 
Exemestane 25 mg orally daily 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Antiestrogens 
SERMs 
Tamoxifen 20 mg orally 
daily 
Hot flushes, vaginal discharge, mild 
nausea, thromboembolism , 
endometrial Ca 
Toremifene 60 mg orally 
daily 
 
 
SERDs 
Fulvestrant 250 mg i.m. 
every 28 
days 
Hot flushes , injection site reactions , 
thromboembolism 
 
 
 
 
 
 
 
 
 
 
 
 
  
ANDROGENS 
Fluoxymestrone 10 mg orally twice a day 
 
 
ESTROGENS 
Diethylstilbestrol 5 mg orally 3 times a day 
Ethinylestradiol 1 mg orally 3 times a day 
Conjugated estrogens 2.5 mg orally 3 times a day 
 
 
LHRH analogs 
Goserelin 3.6 mg s.c. every 28 days 
Leuprolide 3.75 mg i.m. every 28 days 
Triptorelin 3.75 mg i.m. every 28 days 
 
 
PROGESTINS 
Megestrol acetate 40 mg orally four times a day 
Medroxyprogesterone 400-1000mg i.m. every week 
 
 
 
ESTROGEN RECEPTORS IN BREAST CANCER 
          Estrogen is a steroid hormone, synthesized by ovaries and 
other tissues, that is essential for normal mammary development as 
well as lactation.  Estrogen mediates its activities in target tissues by 
activating estrogen receptors, which exhibit transcriptional 
(genomic) and membrane localised (nongenomic) signalling 
activities. The transcriptional activity in targeted tissue occurs in co-
operation with coactivator proteins that interact directly or indirectly 
with estrogen responsive genes facilitating mammary tissue 
proliferation.  
          The physiologic functions of estrogen signalling pathways are 
co-opted in breast cancer to promote cancer progression. There are 
two major receptors for estrogen of the nuclear hormone receptor 
family, ERα and ERβ.  The majority of the breast cancers i.e., 70% 
expresses the estrogen receptor.  
           The estrogens are a family of hormones synthesized in a 
variety of  tissues. 17 - estradiol is the primary estrogen of ovarian 
origin . In pregnancy, relatively more estriol is produced and this 
comes from placenta. 
       
 
 
 
 
 
 
 
    
 Estrogens are formed by the aromatization of androgens in a 
complex process that involves three hydroxylation steps ; each of 
which requires 02 and NADPH .The aromatase enzyme complex is 
thought to include a P450 monooxygenase. Estradiol is formed if the 
substrate of this enzyme complex is testosterone, whereas estrone 
results from the aromatization of androstenedione. 
           Theca cells are the source of androstenedione and 
testosterone; these are converted by the aromatase enzyme in 
granulosa cells to estrone and estradiol,  respectively .          
 
 
 
 
 
 
 
 
 The whole concentration of estradiol in plasma during  
menstrual cycle comes from the ovary and there are two peaks of 
secretion : one just before ovulation and one during the midluteal 
phase . 
The estradiol secretion rate is : 
Early follicular phase  -  36 microgm / day 
Just before ovulation   -  380 microgm / day 
During midluteal phase - 250 microgm / day  
           
 
 
 
 
 
 
 
 After menopause, estrogen secretion declines to low levels. 
The human ovaries become unresponsive to gonadotropins with 
advancing age and their function declines, so that sexual cycles 
disappear (menopause). This unresponsiveness is associated with 
and probably caused by a decline in the number of primordial 
follicles. The ovaries no longer secrete progesterone and 17-  
estradiol in appreciable quantities and estrogen is formed only in 
small amounts of aromatization of androstenedione in peripheral  
tissues.  
           Significant amounts of estrogens are produced by the 
peripheral aromatization of androgens. In females, adrenal 
androgens are important substrates since as much as 50% of the 
estradiol produced during pregnancy comes from the aromatization 
of androgens. Conversion of androstenedione to estrone is the major 
source of estrogens in postmenopausal women. Aromatase activity is 
present in adipose cells and also in liver, skin and other tissues. 
        In 1923, an ovarian hormone regulating mammary tissue, 
estrogen was discovered by Drs. Edgar Allen and Edward Doisy. 
Nearly 40 years passed, until Jensen and Jacobson synthesized 
radioactive estradiol (E2). The observation of tissue specific 
localisation of E2 led to the hypothesis that there is a specific 
estrogen receptor. 
          In 1966, the estrogen receptor was purified and characterised, 
leading to the subsequent findings that breast tissue expresses ER 
and some breast cancers contain ER. Furthermore E2 was linked to 
cellular proliferation and differentiation in normal tissues .The 
concentration range under which hormone binding occurs varies 
depending on biologic conditions. E2 concentrations much lower 
than 10-12 M are capable of stimulating ER function. 
 
 
 
 
 
 
 
ESTROGEN RECEPTORS 
           Like other steroids, estrogens combine with protein receptors 
in the nucleus and the complexes bind to DNA, promoting formation 
of mRNAs that in turn direct the formation of new proteins which 
modify cell function. 
Two nuclear estrogen receptors have been cloned : 
ER α    -  encoded by a gene on chromosome 6 
ER β    -  encoded by a gene on chromosome 14.  
Although there is overlap, the distribution of these receptors is 
different. 
ER α   - expression is moderate to high in : 
Uterus, testis, breast, cervix , vagina, pituitary, kidney, 
epididymis and adrenal. 
ER β   - expression is high in : 
Ovary, prostate, lung, bladder and vascular tissue. 
Both ER α  and ER β in  : 
Brain, CVS and bone. 
It has been suggested that the regulation of ovarian function by 
the pituitary ovarian axis is primarily ER α  mediated ;  whereas the 
estrogens secreted into the ovarian follicles act primarily via ER βs.                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 STRUCTURE OF ESTROGEN RECEPTORS 
                The two forms of the ER , ER α  and  ERβ  are encoded by 
different genes . ESR1 maps to chromosome 6q25.1 whereas ESR2 
maps to 14q23.2. After translation , ERs are initially complexed with 
heat shock protein 90 ( Hsp 90 ) ; they then dimerize when exposed 
to estrogen. Dimerization can also be facilitated by DNA binding  
.  
             ER α ( ESR1 ) and ER  β  ( ESR 2 )  may form homodimers 
or heterodimers. The six domains of ER α  and ER β   are from N   to 
C  terminus. A/B  containing transcription activating domain  AF1 ; 
C containing the DNA binding domain ; D, which is an interdomain  
region ; E, which is a ligand binding domain containing transcription 
activating domain AF2 ; F , which contains the C terminal domain . 
 
 
 
  
STRUCTURE OF THE ESTROGEN RECEPTOR 
The A/B contains the activator function region  AF1. 
C domain contains – DNA binding domain . 
D domain is a spacer. 
E domain contains ligand binding function.  
E domain also contains the activator region AF2. 
F domain is a carboxy terminal domain.   
   A / B      C     D           E       F 
 DNA  LIGAND BINDING  
    AF1             AF2 
 
 
 
N C 
Molecular Cloning and Characterization of The Estrogen Receptors 
              There are two ubiquitous ERs, ER α and ERβ.  But the 
relative abundance of each receptor determines, in part the tissue 
specificityof their effector functions .The molecular era of estrogen 
biology began with the molecular cloning  and sequencing of the 
ERα  - c DNA  and its gene (ESR1). 
           Both estrogen receptors exhibit E2 – dependent DNA binding 
and mediate transcriptional regulation through interaction with 
estrogen response elements ( EREs ) that may promote or inhibit 
transcription  
            ER α exhibits regulatory phosphorylation sites at Ser106, 
Ser118, Ser236 and Tyr537 among others .In addition to epidermal 
growth factor signalling, which can activate ER-mediated 
transcription through MAPkinase – mediated ER  phosphorylation, 
the IGF pathway can also promote ER-mediated transcription .  
 
 
EXPRESSION OF ESTROGEN RECEPTORS IN                                                
BREAST CANCER 
           About 70% of breast cancers express ER α detectable by 
immunohistochemistry. The expression of ER α  in breast cancer is 
constitutive, in contrast to the normal mammary epithelium, where 
proliferating cells fail to exihibit ER expression and ER α      
expression is confined to a small proportion of non proliferating 
luminal cells .  
             It has been hypothesized that ER α could play a role in the 
etiology of breast cancer under conditions of prolonged exposure to 
estrogens such as those occurring with early menarche, late 
menopause, obesity or hormone replacement therapy. Prolonged 
exposure to E2 could lead to increased proliferation of mammary 
epithelial cells, increasing the risk of mutation events. Another 
hypothesis is that high E2 levels lead to increased  metabolism of E2 
to carcinogenic derivatives such as the reactive catechol 4-hydroxy-
E2 which can damage DNA and lead to mutation .  
 
             ER α and immunohistochemical detection of ER α is 
predictive of response to hormonal therapy. ER α is cyclically 
regulated to the menstrual cycle in normal mammary tissue, but it is 
constitutively expressed in the most common subtypes of human 
breast cancer wherein it functions as a master regulator, promoting 
breast cancer growth and disease progression . 
 
             In contrast ER β exhibits an overlapping but distinct, tissue 
distribution of its pattern of expression in mammary tissue, 
cardiovascular tissue, the gastrointestinal tract and bone. The role of 
ER β  in breast cancer is less well characterised. 
 
            On the basis of extensive clinical trial data in the 1970s and 
since then , ER α has been developed clinically as classifier of breast 
cancers that respond to hormonal therapy. ER α  can be targeted with 
selective estrogen receptor modulators (SERMS ) such as  tamoxifen 
that compete with estrogen and alter the conformation  of the ligand 
–binding of the receptor. SERMs such as tamoxifen are effective in 
the metastatic and adjuvant settings and tamoxifen itself has also 
been successful in chemoprevention of breast cancer in women with 
elevated risk of breast cancer. Another approach for hormonal 
therapy is exemplified by the antiestrogen drug fulvestrant which 
promotes proteolytic degradation of ER . 
 
 
 
 
 
 
 
 
 
 
 
STEROID HORMONE RECEPTOR IN CA BREAST 
            Hormones play an important role in the development and 
progression of breast cancer. Estrogens, estrogen metabolites and 
progesterones have been shown to have some effect. Breast cancer 
risk is related to estrogen exposure over time. In postmenopausal 
women, hormone replacement therapy increases the risk of breast 
cancer by 26%. 
            Patients with hormone receptor positive tumors survive two 
to three times longer after a diagnosis of metastatic disease than do 
patients with hormone receptor negative tumors. Patients with 
tumors negative for both estrogen receptors and progesterone 
receptors are not considered candidates for hormonal therapy. 
Tumors positive for estrogen or progesterone receptors have a higher 
response rate to endocrine therapy than tumors that do not express 
estrogen or progesterone receptors. Tumors positive for both 
receptors have a response rate of  > 50% ; tumors negative for both 
receptors have a response rate < 10%  and tumors positive for one 
receptor but not the other have an intermediate response rate of  
33%. 
         The tumor hormone receptor status should be ascertained for 
both premenopausal and postmenopausal patients to identify patients 
who are most likely to benefit from endocrine therapy. Estrogen and 
progesterone receptor status can be measured in archived tissue 
using immunohistochemical techniques. Hormone receptor status 
also can be measured in specimens obtained with fine- needle 
aspiration or core needle biopsy and this can help in planning the 
treatment. 
          In a landmark breast cancer  prevention study, tamoxifen 
exhibited efficacy as a preventive agent in patients with increased 
risk for breast cancer estimated by the Gail model , demonstrating 
proof of principle of chemoprevention in “at risk” patient population 
( National Surgical Adjuvant Breast and Bowel Project [ NSABP ] 
P-1 ). 
          Although ER is predictive of response to hormonal therapy 
rather than prognostic, a prognostic risk model for recurrence in 
patients with ER – positive breast cancer receiving adjuvant 
tamoxifen has been developed. 
           The utility of ER testing was subsequently established when 
investigators found that patients responding to tamoxifen exhibited  
higher levels of ER , leading to the further study and refinement of 
endocrine therapy for ER – positive breast cancer in clinical trials 
during the past 40 years . 
           Most notably researchers demonstrated that 5 years of 
tamoxifen was effective for prevention of breast cancer recurrence  
when added to adjuvant chemotherapy in node positive patients.               
 
 
 
 
 
 
 
 
 
ESTROGEN RECEPTOR AND HORMONAL STATUS 
          The reason for the cytosolic estrogen receptor (CER) 
increasing with patient age may be related to a number of factors . 
Since postmenopausal women have lower circulating estrogen 
levels, the higher CER levels observed in tumors from these patients 
have been suggested to be the result of an increase in unoccupied 
cytosolic receptor rather than an increase in total cytosol receptor.  
              Saez et al. have postulated that the cyclic levels of serum 
progesterone in premenopausal patients limit CER synthesis .This 
later hypothesis is supported by the menstrual cycle variations of 
CER observed in normal human endometrium. In both the breast and 
endometrium, preluteal CER values were significantly higher than 
CER levels during the luteal phase when plasma progestin is high . 
Thus the higher CER levels observed in postmenopausal patients 
may be related to chronic unopposed estrogen stimulation to a 
decrease in the progesterone down-regulation of CER or a 
combination of these factors. 
 
ER POSITIVITY IN POSTMENOPAUSAL WOMEN 
          Postmenopausal patients had significantly higher CER levels 
than premenopausal patients. The cumulative distribution of CER by 
menstrual status demonstrated a higher percentage of premenopausal 
patients with unmeasurable CER levels. 
Examination of the CER values against age revealed steadily 
increasing CER values with age from third decade into the tenth 
decade. Tumors in patients < 35 years had quantitatively lower 
receptor values. 
          ER positivity increases in postmenopausal women. This may 
be seen as unusual because the ovaries may stop producing estrogen 
.In postmenopausal women, body fat still produces estrogen. But in 
this low estrogen environment , the breast cancer tries to expand the 
number of locks – the estrogen receptors – inside the tumor ; so that 
it can capture these very, very, small levels of estrogen . So estrogen 
receptor levels tend to be higher in postmenopausal women than in 
premenopausal women.  
           The integrity of receptor regulation of breast carcinoma 
growth is reflected in the tumor’s biologic behaviour. The improved 
survival and response rate to hormonal therapy observed in elderly 
patients with breast carcinoma suggests that these patients would be 
more likely to have an intact receptor control mechanism, compared 
with younger patients. 
 
 
 
 
 
 
 
 
 
 
SIGNIFICANCE OF ER STATUS 
1. The frequency of ER positivity increase steadily with age. 
2. The concentration and proportion of ER positivity were 
higher in postmenopausal than in premenopausal patients. 
3. The level of ER positivity decreases with stage 
advancement. 
4. Level of ER positivity decreases with increasing size of the 
primary tumor . 
5. The more the concentration of ER, the little the chance to 
develop distant metastases . 
6. ER assessment is essential for determining postoperative 
treatment modality . 
7. ER positive patients receiving hormonal treatment have 
better prognosis . 
 
 
 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry otherwise called 
immunocytochemistry, is a method by which we identify specific 
antigens in tissues or cells . this is based  antigen – antibody 
recognition ;One of the sensitive detection system is the enzymatic 
label  (horseradish peroxidase) developed by Avrameas and 
colleagues, which ,in the presence of a suitable colorogenic substrate 
system,  allowed visualization of the labelled antibody by orthodox 
light microscopy.  Multiple– step detection techniques such as the 
peroxidase  antiperoxidase (PAP), avidin–biotin conjugate ( ABC ) 
and biotin – streptavidin (B-SA)  methods, together with 
amplification methods (such as tyramide) and the highly sensitive 
“polymer based” labelling systems. 
The development of the hybridoma technique facilitated the 
development of IHC and the manufacture of abundant, highly 
specific monoclonal antibodies, many of which found early 
application in staining of tissues. Initial success in cryostat sections 
was eventually extended to routinely processed paraffin, celloidin, or 
other plastic – embedded tissue sections. The critical significance of 
rendering the IHC technique suitable for routine paraffin sections 
was illustrated by Taylor and colleagues, who in 1974 showed that it 
was possible to demonstrate at least some antigens in routinely 
processed tissue. The collective appetites of pathologists worldwide, 
once whetted by these initial studies, led to serious attempts to 
improve further the ability to perform IHC staining on formalin –
paraffin sections. Although great effort has been expended in the 
search for alternative fixatives (formalin fixatives) in order to 
preserve antigenicity without compromising preservation of 
morphologic features, no ideal fixatives have been found to date , as 
was pointed out by Larsson who said, “An ideal immuno 
cytochemical fixative applicable to all antigens may never be 
found”. In addition, preservation of morphologic features is not 
always comparable with formalin fixation. 
Enzyme digestion was introduced by Huang and colleagues as 
a pretreatment to IHC staining to “unmask” some antigens that had 
been altered by formalin fixation. However, the enzyme digestion 
method, while widely applied , did not improve IHC staining of the 
majority of antigens, as reviewed by Leong and colleagues . Another 
drawback of enzyme digestion was that it proved difficult to control 
the optimal digestion conditions for individual tissue sections when 
stained with different antibodies. These difficulties in 
standardization provided a powerful incentive for the development 
of a new technique, with that it should be more powerful, more 
widely applicable and easier to use than enzyme digestion. In 
addition, it should enhance immunohistochemical staining of 
routinely formalin fixed, paraffin embedded tissue sections in a 
reproducible and reliable manner. 
The antigen retrieval technique, based on a series of 
biochemical studies by Fraenkel-Conrat and coworkers, was 
developed by Shi and associates in 1991 .In contrast to enzyme 
digestion, the AR technique  is a simple method that involves 
heating routinely processed paraffin sections at high temperature 
(e.g., in a microwave oven) before IHC staining procedures. An 
alternative method that did not use heating was developed for 
celloidin-embedded tissues. The intensity of IHC staining was 
increased dramatically after AR pretreatment, as demonstrated by 
the original articles and more than 100 articles published 
subsequently. Various modifications of AR technique have been 
described, the majority of which use different buffer solutions as the 
AR solution in place of metal salt solutions, which may have a 
potentially toxic effect. Worldwide applications of AR-IHC in 
pathology has validated the feasibility of AR-IHC and expanded its 
use in molecular morphology.   
 
 
 
 
 
 
 
 
 
 
 BASIC PRINCIPLES OF IMMUNOHISTOCHEMISTRY 
 In certain circumstances, the histochemical stains is proved to 
be of critical value in specific cell identification. More often, they 
served merely to highlight or emphasize cellular or histologic 
features that supported a particular interpretation without providing 
truly specific confirmation . Now-a –days there is possibility to use 
specific stains in the field of immunohistochemistry . 
 
The aims of IHC are akin to those of histochemistry. Indeed, 
IHC builds on the foundations of histochemistry ;  it does not replace 
histochemistry but rather serves as a valuable adjunct that greatly 
extends the variety of tissue components that can be demonstrated 
specifically within tissue sections or other cell preparations. . The 
basic critical principle of IHC, as with any other special staining 
method, is a sharp localization of target components in the cell and 
tissue, based on a satisfactory signal-to –noise ratio. Amplifying the 
signal while reducing nonspecific background staining (noise) is the 
major strategy to achieve a satisfactory and practically useful result. 
After more than two decades, advances in IHC have provided a 
feasible approach to performing immunostaining on routinely 
processed tissues.  
 
 
 
 
 
 
 
 
 
 
 
 
 ANTIBODIES AS SPECIFIC STAINING REAGENTS 
Evaluation of an antibody for use in IHC is based on 
sensitivity and specificity of the antigen-antibody reaction for IHC. 
Although the specificity of monoclonal antibody has been 
questioned regarding cross-reactivity with nontarget molecules, most 
commercially available monoclonal antibodies are highly reliable for 
IHC. 
 
 
 
 
 
 
 
 
TISSUE FIXATION AND PROCESSING 
Tissue preparation consists of fixation, subsequent dehydration 
and embedment in paraffin wax to provide a rigid matrix for 
sectioning .Tissues that are to be embedded in paraffin wax are first 
fixed in order to optimize preservation, a process that profoundly 
affects the morphologic and immunohistologic results. The ideal 
fixative for IHC studies should not only be readily available but 
should also be in widespread use to maximize the range and number 
of samples available for IHC studies .The fixative should preserve 
antigenic integrity and should limit extraction, diffusion or 
displacement of antigen during subsequent processing . 
Common fixatives used in histopathology are divided into two 
groups: coagulant fixatives, such as ethanol and cross linking 
fixatives such as formaldehyde. Both types of fixatives can cause 
changes in the steric configuration of proteins, which may mask 
antigenic sites (epitopes) and adversely affect binding with antibody. 
It is well recognized that cross linking fixatives alter the IHC results 
for a significant number of antigens, whereas coagulant fixatives, 
especially ethanol, have been reported to produce lesser changes. In 
most surgical pathology laboratories, the fixative used is 10% 
neutral buffer formalin (NBF) (a cross-linking fixative). Subsequent 
processing usually includes a period in 100% ethanol ; thus tissues 
are effectively double fixed in both formalin and ethanol . A long 
history of using formalin as a standard tissue fixative has revealed 
the following advantages : 
1. There is good preservation of morphology for a variety of 
tissues, even after prolonged fixation. 
2. Formalin is an economical chemical, much cheaper than most 
alternatives. 
3. Formalin fixation can sterilise tissue specimen in a more 
reliable way than precipitating fixatives, particularly for 
viruses  
4. Carbohydrate antigens are better preserved . 
5. There is preservation of many antigens through cross-linking 
of protein in situ, thereby avoiding leaching out of proteins 
that may diffuse in water or alcohol. 
Formalin may be regarded as a satisfactory fixative for both 
morphology and IHC provided that a simple and effective AR 
technique is available to recover those antigens that are diminished 
or modified. 
 
 
 
 
 
 
 
 
 
 
 
 
HORMONE RECEPTORS IN IMMUNOHISTOCHEMISTRY 
Estrogen receptors bind hormones that exert their effects in the 
nucleus. Nuclear immunostaining for estrogen receptor proteins can 
be demonstrated in normal breast acini, which serve as internal 
controls for the testing procedure. Nuclear staining in normal breast 
tissue is heterogenous and varies with the menstrual cycle. 
Since the early 1990s, the immunohistochemical assay ( ICA ) 
determination of ER levels has replaced the dextran –coated charcoal 
( DCC ) method .Some of the advantages of the ICA method 
include: 
1. histologic documentation of the tumor tissue to be assayed . 
2. appreciation of the heterogeneity of ERs in tumor nuclei . 
3. rapid turnaround time. 
4. lower cost. 
5.  ability to use minute quantities of tissue. 
Some of the first ICA antibodies to be used would work well 
only on frozen tumor samples. The H222 antibody functioned well 
on frozen tissue , but subsequently studies on formalin – fixed, 
paraffin embedded tissues stressed the importance of short ( < 24 hr) 
formalin fixation times for optimal results . 
The appearance of second generation ER antibodies ( ER1D5 , 
DAKO,  Carpinteria ,  CA ) combined with newer antigen retrieval 
methods has rendered the DCC method obsolete . 
Pertschuk and colleagues and Taylor and associates argued 
that using a percentage of nuclear staining of 10% as a minimum for 
a positive result was reproducible and correlated well clinically. 
Barnes and colleagues used a triad of staining intensity, 
percent positive cells and degree of heterogeneity of staining to 
arrive at an index number that is predictive of endocrine response. 
The fact that ER by IHC can be performed on minute 
quantities of tissue is a distinct advantage, especially for patients 
with a diagnosis of carcinoma by FNA. 
Rosen was the first to describe tumor histopathologic 
correlations with ER expression. Tumor types that tend to be ER+ 
include tubular, mucinous, and papillary carcinomas, along with 
ductal carcinomas of low nuclear grade.     
  
MATERIALS AND METHODS 
Government Rajaji Hospital is a tertiary care centre in 
Madurai, Tamilnadu. It has the privilege of having maximum 
number of outpatients in South Tamilnadu.  
Carcinoma breast is one of the common surgical problems 
presenting to our everyday outpatient department. Modified radical 
mastectomy is a common surgical procedure being performed in our 
operation theatres. 
The purpose of this study is to compare the “Estrogen 
Receptor Status” between premenopausal and post menopausal  
women with carcinoma breast . 
Duration of the study      :  from September 2010 to August 2012 . 
 
 
 
SELECTION OF STUDY SUBJECTS 
 
Genders eligible for study  :  Females only . 
Age eligible for study   : 
Premenopausal    :  30-40 years 
Postmenopausal    :  > 50 years 
 
INCLUSION CRITERIA : 
1. All patients with carcinoma breast attending the out patient 
department of surgery at Government Rajaji Hospital, Madurai 
are included .The clinical finding should be in favour of 
carcinoma breast .The malignancy should be proved either by 
FNAC or Trucut biopsy – HPE report . 
2. The patient should have a clearcut menstrual history with 
regular menstrual periods . 
 
 
 
 
EXCLUSION CRITERIA : 
 
1. Patients with intake of exogenous estrogen exposure in the 
form of  “Hormone Replacement Therapy” or prolonged 
intake of OCP . 
2. Patients who had undergone hysterectomy previously ie. 
Surgical menopause. 
 
 
 
 
 
 
 
 
 
 
 
DATA COLLECTION : 
1. Menstrual History in detail  
Premenopausal 
- Age at menarche 
- Menstrual cycles  regular / irregular 
- Length of each cycle 
- LMP 
Postmenopausal  
- Age at menarche 
- Age at menopause 
- Last menstrual cycle  
2.  Marital status 
3.  Parity 
4. Age of first child birth 
5. Breast feeding history 
- whether each child was breastfed or not ? 
- if breastfed / for  how long ? 
- whether both breasts were equally used ? 
6. Drug history : 
H/O prolonged OCP intake 
H/O hormone replacement therapy 
7. Family history 
8. Clinical finding in favour of CA Breast 
9. Investigation in favour of CA Breast 
- FNAC report 
-  Trucut  biopsy HPE report 
 
 
 
 
  
ER STAINING 
 
 
 
 
 
 
Reference Range  
Quick Score  =  0-8 
Proportion  
0  =  No nuclear staining 
1 =  < 1% nuclei staining 
2  =  1-10 % nuclei staining 
3  =  11-33 % nuclei staining 
4 =  34-66% nuclei staning 
5 =  67-100% nuclei staining 
INTENSITY 
0 = No staining 
1 =  Weak staining  
2 =  Moderate staining 
3 = Strong staining 
INTERPRETATION 
Patients with tumors scoring 2 or less are regarded as ER 
negative and have a negligible chance of response to therapy . 
 RESULTS 
Table -1 
Age Distribution for Pre menopausal 
 
PRE MENOPAUSAL 
Age Positive Negative Total 
30 - 35   0 4 4 
36 - 40   16 5 21 
Total 16 9 25 
Mean age 36.84 
S.D 1.97 
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Table -2 
Age Distribution for Post menopausal 
 
POST MENOPAUSAL 
Age Positive Negative Total 
50 - 60 15 4 19 
61 - 70  4 0 4 
71 - 80   2 0 2 
Total 21 4 25 
Mean 59.0 
S.D 7.86 
P value < 0.001 
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Table -3 
Distribution of Positive and Negative  
 
 
 Positive Negative 
Pre menopausal 16 9 
Post menopausal 21 4 
 
   P value  =  0.367  Not significant  
  (for Premenopausal) 
 
 
   P value  =  0.009   Significant     (4 / 21) 
     (for Post menopausal) 
   
 
 
                   
 
POST MENOPAUSAL
16%
84%
Negative Positive
 
PREMENOPAUSAL
36%
64%
Negative Positive
 
DISCUSSION 
Fifty patients with breast cancer included in this study, were 
divided into two subgroups. 25 premenopausal patients with age 
ranging from 30-40 and mean age 36.8 and post menopausal patients 
with age ranging from 50-80, with mean age 59.0 years.  
Left breast was involved in 92 % of the cases and upper outer 
quadrant was the commonest site affected. Infiltrating ductal 
carcinoma was the underlying pathology in all the cases. 
Estrogen receptor positivity was higher in postmenopausal 
patients (84%) than in premenopausal patients (64%). The difference 
is statistically significant. 
The analyses of the data from patients with primary carcinoma 
of the breast indicate that CER increases with age from the third 
through the seventh decade. Most previous studies have emphasized 
menopausal status, suggesting that premenopausal patients have a 
lower incidence of CER positive tumors as well as quantitatively 
lower tumor levels of estrogen receptor compared with 
postmenopausal patients. 
Martin et al found that although mean CER levels increased 
for each decade, significant difference were only noted between 
premenopausal and postmenopausal patients.  
Similar study was conducted from Mansoura university from  
August 1986 to November 1987 , published in science and medical 
journal, vol.2 ,April 1990 . Estrogen receptor positivity was higher 
in postmenopausal patients than premenopausal patients. Hormonal 
treatment in estrogen receptor positive patients resulted in least 
number of failure of the treatment. 
Patients of age group 45-65 years exhibited the higher 
frequency of estrogen receptor positivity than patients of age group 
20-44 years. The difference was statistically significant ; this is in 
agreement with that previously reported by Pascual et al ( 1982) and 
Chua et al ( 1985 ) 
ER positivity in postmenopausal females was higher than ER 
positivity in premenopausal females and this finding confirms the 
results obtained by Aboul Enein et al ( 1983 ). 
This may be due to the elevated level of endogenous estrogen 
in plasma of premenopausal women which may mask receptor 
binding sites. ( Hawkins et al . 1980 and knight et al. 1980). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
In  this study 50 post mastectomy specimens were collected     
(25-premenopausal and 25-postmenopausal) and subjected to 
estrogen receptor assay by biochemical monoclonal antibody 
method. Estrogen receptor status was correlated with age and 
menstrual status. 
• The frequency of ER positivity increase steadily with age. 
• The concentration and proportion of ER positivity were 
higher in postmenopausal than in premenopausal patients. 
• ER assay is recommended as a routine test in the 
management of breast cancer because of its help in 
predicting the response to hormonal therapy, in addition its 
an important prognostic factor. 
 
 
 
  
LIMITATIONS OF THE STUDY 
 
1. Sample size should be more. 
2. Technical problems in immunohistochemistry : like 
problems in fixation ; processing problems ; imprecise 
sectioning ; inappropriate staining. 
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PROFORMA 
Name   :    Age &  Sex   : 
IP No.   :    Unit  : 
Occupation  : 
Address  : 
Date of Admission :    Date of discharge : 
Age at menarche :    Age of menopause : 
Menstrual history : Regular / Irregular 
    Length of cycle 
    LMP 
Marital status :    Parity : 
Breast feeding Details : 
 Whether each child was breast fed or not 
 If breast fed for how long ? 
 Whether both breasts were equally used 
Drug History   : HRT / OCP 
Family History :  
Clinical finding in favour of CA breast 
Investigation in favour of CA breast 
FNAC report    or  
Trucut biopsy report 
Investigation to be studied  : 
ER Status in post mastectomy specimen 
  
 
MASTER CHART FOR POST MENOPAUSAL PATIENTS 
S.No. Name Age 
Side of CA 
Breast IP No. 
Marital 
Status Parity Breast feeding details HRT ER Status 
1 Veerammal 70 left 73241 married P3 breastfed adequately Nil positive 
2 Krishnaveni 50 left 453219 married P2 breastfed adequately Nil negative 
3 Arayee 50 left 46789 married P2 breastfed adequately Nil negative 
4 Muthulakshmi 58 left 45759 married P3 breastfed adequately Nil positive 
5 Glori 80 left 74523 married P4 breastfed adequately Nil positive 
6 Arasammal 75 left 45326 married P4 breastfed adequately Nil positive 
7 Muniyammal 65 left 76894 married P5 breastfed adequately Nil positive 
8 Kaliammal 55 left 45423 married P3 breastfed adequately Nil positive 
9 Neela 60 left 48763 married P2 breastfed adequately Nil positive 
10 Lakshmi 60 left 45908 married P2 breastfed adequately Nil positive 
11 Dhanalakshmi 50 left 43984 married P2 breastfed adequately Nil positive 
12 Shabitha 55 left 75569 married P3 breastfed adequately Nil positive 
13 Sivagami 57 left 76142 married P3 breastfed adequately Nil positive 
14 Saraswathi 69 left 3897 married P3 breastfed adequately Nil positive 
15 Annammal 50 left 63786 married P2 breastfed adequately Nil positive 
16 Rajeshwari 55 left 23678 married P2 breastfed adequately Nil positive 
17 Mariyambeevi 60 left 59987 married P3 breastfed adequately Nil positive 
18 Ramayee 60 left 56732 married P3 breastfed adequately Nil positive 
19 Panchavarnam 51 right 87543 married P2 breastfed adequately Nil positive 
20 Mariyammal 56 right 58762 married P2 breastfed adequately Nil positive 
21 Rajammal 51 right 98712 married P3 breastfed adequately Nil negative 
22 Avudaiyammal 60 left 90078 married P3 breastfed adequately Nil positive 
23 Janakiammal 62 right 50065 married P4 breastfed adequately Nil positive 
24 Thangam 53 left 76985 married P2 breastfed adequately Nil negative 
25 Rani 58 left 63489 married P2 breastfed adequately Nil positive 
 
 
 
 
 
 
 
 
 
MASTER CHART FOR PRE MENOPAUSAL PATIENTS 
S.No. Name Age 
Side of CA 
Breast IP No. 
Marital 
Status Parity 
Breast feeding 
details HRT 
ER 
Status 
1 Gandhimathi 39 left 93419 married P2 breastfed adequately Nil positive 
2 Nanjammal 39 left 68768 married P3 breastfed adequately Nil positive 
3 Shenbagavalli 38 left 58802 married P3 breastfed adequately Nil positive 
4 Kalyani 37 left 85107 married P2 breastfed adequately Nil positive 
5 Amaravathi 36 left 34214 married P2 breastfed adequately Nil positive 
6 Gowri 38 left 36432 married P1 breastfed adequately Nil positive 
7 Shantha 36 left 98765 married P1 breastfed adequately Nil positive 
8 Janaki 35 left 13567 married P2 breastfed adequately Nil negative 
9 Nirmalanavamani 38 left 65438 married P3 breastfed adequately Nil positive 
10 Latha 38 left 65457 married P2 breastfed adequately Nil positive 
11 Pounthai 30 left 96473 married P2 breastfed adequately Nil negative 
12 Muthuselvi 36 left 10362 married P2 breastfed adequately Nil positive 
13 Chithra 38 left 8921 married P3 breastfed adequately Nil positive 
14 Packiam 34 left 41321 married P2 breastfed adequately Nil negative 
15 Kamatchi 37 left 34865 married P1 breastfed adequately Nil positive 
16 Murugeswari 37 left 80178 married P2 breastfed adequately Nil negative 
17 Meenakshi 36 left 83969 married P2 breastfed adequately Nil negative 
18 Selvi 37 left 88653 married P3 breastfed adequately Nil negative 
19 Nisha 38 left 77632 married P3 breastfed adequately Nil positive 
20 Sundari 39 left 73902 married P2 breastfed adequately Nil positive 
21 Priya 38 left 21576 married P2 breastfed adequately Nil positive 
22 Bhanu 36 right 26207 married P2 breastfed adequately Nil negative 
23 Vellayammal 39 right 62564 married P3 breastfed adequately Nil positive 
24 Nagammal 35 right 57080 married P2 breastfed adequately Nil negative 
25 Saraswathi 37 right 73591 married P2 breastfed adequately Nil negative 
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